IV consenso mexicano sobre Helicobacter pylori

Desde el último consenso mexicano para el diagnóstico y tratamiento de la infección por Helicobacter pylori (H. pylori) en el 2007, han existido avances importantes al respecto. Por tal motivo, la Asociación Mexicana de Gastroenterología convocó a 20 expertos para la realización del «IV consenso mexicano sobre H. pylori». Durante febrero y junio del 2017 se organizaron 4 mesas de trabajo, una revisión de la literatura y 3 rondas de votaciones donde se establecieron 32 enunciados para discusión y consenso. Dentro de las recomendaciones se destaca el reconocer a México como un país con riesgo de cáncer gástrico bajo a intermedio a pesar de la alta prevalencia de infección por H. pylori. Se corrobora que enfermedad ulcerosa péptica, presencia de lesiones premalignas, antecedentes de cáncer gástrico y linfoma asociado a la mucosa deben considerarse indicaciones claras para erradicación. La relación del H. pylori con los síntomas dispépticos sigue siendo controversial. La triple terapia de erradicación con amoxicilina, claritromicina y un inhibidor de la bomba de protones ya no debe ser considerada la primera línea de tratamiento. En su lugar, se proponen 2 opciones: la terapia cuádruple con bismuto (inhibidor de la bomba de protones, subcitrato de bismuto, tetraciclina y metronidazol) y la terapia cuádruple sin bismuto (inhibidor de la bomba de protones, amoxicilina, claritromicina y metronidazol). Se establece la necesidad de la realización de sensibilidad antimicrobiana ante la falla a 2 tratamientos de erradicación. Finalmente, se proponen campañas de educación respecto al diagnóstico y tratamiento del H. pylori para médicos de primer contacto y población general. Abstract Important advances have been made since the last Mexican consensus on the diagnosis and treatment of Helicobacter pylori (H. pylori) infection was published in 2007. Therefore, the Asociación Mexicana de Gastroenterología summoned 20 experts to produce ‘‘The Fourth Mexican Consensus on Helicobacter pylori’’. From February to June 2017, 4 working groups were organized, a literature review was performed, and 3 voting rounds were carried out, resulting in the formulation of 32 statements for discussion and consensus. From the ensuing recommendations, it was striking that Mexico is a country with an intermediate-to-low risk for gastric cancer, despite having a high prevalence of H. pylori infection. It was also corroborated that peptic ulcer disease, premalignant lesions, and histories of gastric cancer and mucosaassociated lymphoid tissue lymphoma should be considered clear indications for eradication. The relation of H. pylori to dyspeptic symptoms continues to be controversial. Eradication triple therapy with amoxicillin, clarithromycin, and a proton pump inhibitor should no longer be considered first-line treatment, with the following 2 options proposed to take its place: quadruple therapy with bismuth (proton pump inhibitor, bismuth subcitrate, tetracycline, and metronidazole) and quadruple therapy without bismuth (proton pump inhibitor, amoxicillin, clarithromycin, and metronidazole). The need for antimicrobial sensitivity testing when 2 eradication treatments have failed was also established. Finally, the promotion of educational campaigns on the diagnosis and treatment of H. pylori for both primary care physicians and the general population were proposed

Consenso Mexicano para el Tratamiento de la Hepatitis C

El objetivo del Consenso Mexicano para el Tratamiento de la Hepatitis C fue el de desarrollar un documento como guía en la práctica clínica con aplicabilidad en México. Se tomó en cuenta la opinión de expertos en el tema con especialidad en: gastroenterología, infectología y hepatología. Se realizó una revisión de la bibliografía en MEDLINE, EMBASE y CENTRAL mediante palabras claves referentes al tratamiento de la hepatitis C. Posteriormente se evaluó la calidad de la evidencia mediante el sistema GRADE y se redactaron enunciados, los cuales fueron sometidos a voto mediante un sistema modificado Delphi, y posteriormente se realizó revisión y corrección de los enunciados por un panel de 34 votantes. Finalmente se clasificó el nivel de acuerdo para cada oración. Esta guía busca dar recomendaciones con énfasis en los nuevos antivirales de acción directa y de esta manera facilitar su uso en la práctica clínica. Cada caso debe ser individualizado según sus comorbilidades y el manejo de estos pacientes siempre debe ser multidisciplinario. Abstract The aim of the Mexican Consensus on the Treatment of Hepatitis C was to develop clinical practice guidelines applicable to Mexico. The expert opinion of specialists in the following areas was taken into account: gastroenterology, infectious diseases, and hepatology. A search of the medical literature was carried out on the MEDLINE, EMBASE, and CENTRAL databases through keywords related to hepatitis C treatment. The quality of evidence was subsequently evaluated using the GRADE system and the consensus statements were formulated. The statements were then voted upon, using the modified Delphi system, and reviewed and corrected by a panel of 34 voting participants. Finally, the level of agreement was classified for each statement. The present guidelines provide recommendations with an emphasis on the new direct-acting antivirals, to facilitate their use in clinical practice. Each case must be individualized according to the comorbidities involved and patient management must always be multidisciplinary

A global research priority agenda to advance public health responses to fatty liver disease

Background & aims An estimated 38% of adults worldwide have non-alcoholic fatty liver disease (NAFLD). From individual impacts to widespread public health and economic consequences, the implications of this disease are profound. This study aimed to develop an aligned, prioritised fatty liver disease research agenda for the global health community. Methods Nine co-chairs drafted initial research priorities, subsequently reviewed by 40 core authors and debated during a three-day in-person meeting. Following a Delphi methodology, over two rounds, a large panel (R1 n = 344, R2 n = 288) reviewed the priorities, via Qualtrics XM, indicating agreement using a four-point Likert-scale and providing written feedback. The core group revised the draft priorities between rounds. In R2, panellists also ranked the priorities within six domains: epidemiology, models of care, treatment and care, education and awareness, patient and community perspectives, and leadership and public health policy. Results The consensus-built fatty liver disease research agenda encompasses 28 priorities. The mean percentage of ‘agree’ responses increased from 78.3 in R1 to 81.1 in R2. Five priorities received unanimous combined agreement (‘agree’ + ‘somewhat agree’); the remaining 23 priorities had >90% combined agreement. While all but one of the priorities exhibited at least a super-majority of agreement (>66.7% ‘agree’), 13 priorities had 90% combined agreement. Conclusions Adopting this multidisciplinary consensus-built research priorities agenda can deliver a step-change in addressing fatty liver disease, mitigating against its individual and societal harms and proactively altering its natural history through prevention, identification, treatment, and care. This agenda should catalyse the global health community’s efforts to advance and accelerate responses to this widespread and fast-growing public health threat. Impact and implications An estimated 38% of adults and 13% of children and adolescents worldwide have fatty liver disease, making it the most prevalent liver disease in history. Despite substantial scientific progress in the past three decades, the burden continues to grow, with an urgent need to advance understanding of how to prevent, manage, and treat the disease. Through a global consensus process, a multidisciplinary group agreed on 28 research priorities covering a broad range of themes, from disease burden, treatment, and health system responses to awareness and policy. The findings have relevance for clinical and non-clinical researchers as well as funders working on fatty liver disease and non-communicable diseases more broadly, setting out a prioritised, ranked research agenda for turning the tide on this fast-growing public health threat

Calceolaria dichotoma subsp. colimana (Calceolariaceae), a new subspecies from western Mexico [Calceolaria dichotoma subsp. colimana (calceolariaceae), una subespecie nueva del occidente de México]

Calceolaria dichotoma subsp. colimana is described and illustrated as a new subspecies from the state of Colima in western Mexico. C. dichotoma belongs to subgenus Cheiloncos and section Micranthera, previously only known from the Andes, from Colombia to the north of Argentina. The finding of the taxon in Colima increases thousands of kilometers to the north the known distribution of the subgenus, section and species

Interpretation of anthropometric indices in children of Arandas, Jalisco, Mexico [Interpretaci�n de �ndices antropom�tricos en ni�os de Arandas, Jalisco, M�xico]

Objective. To assess the nutritional status of children attending the Instituto Alte�o para el Desarrollo de Jalisco (Highlands Institute for Development of Jalisco State, Inadej) in Arandas, Jalisco and to discuss the classification criteria of infant malnutrition in Mexico. Material and Methods. A cross-sectional study was conducted in 775 children aged between twelve and one hundred and twenty months, who attended Inadej, including 432 children recently registered in INADEJ. Measurements included weight/age, height/age, and weight/height indices. The prevalence of malnutrition was compared using the WHO's criteria and the Mexican Official Norm Classification (NOM-SSA) criteria. The weight/age, height/age and weight/height indices were compared using the chi-squared test. Results. Parents' schooling level was low (mean=3.6 years); the mean family income was U.S. $198.00 dollars per month, with each family member receiving 0.56 dollars per day for three daily meals. The prevalence of malnutrition was significantly higher with any of the three indices when using the NOM-SSA criteria, as compared to the WHO criteria (weight/age 91.7 vs. 30.9%; height/age 66.9 vs 17.3%; and weight/height 62.5 vs. 9.5%, respectively). Conclusions. The weight/age index and the NOM-SSA criteria overestimate the prevalence of malnutrition and are not able to tell apart children with familial small size, nor those with acute and/or chronic or past malnutrition. The WHO criteria were found to be more useful; the weight/height (recent malnutrition) and height/age (chronic malnutrition) indices should be used for international comparisons

[Interpretation of anthropometric indices in children in Arandas, Jalisco, Mexico]

OBJECTIVE: To assess the nutritional status of children attending the Instituto Alteno para el Desarrollo de Jalisco (Highlands Institute for Development of Jalisco State, Inadej) in Arandas, Jalisco and to discuss the classification criteria of infant malnutrition in Mexico. MATERIAL AND METHODS: A cross-sectional study was conducted in 775 children aged between twelve and one hundred and twenty months, who attended Inadej, including 432 children recently registered in INADEJ. Measurements included weight/age, height/age, and weight/height indices. The prevalence of malnutrition was compared using the WHO's criteria and the Mexican Official Norm Classification (NOM-SSA) criteria. The weight/age, height/age and weight/height indices were compared using the chi-squared test. RESULTS: Parents' schooling level was low (mean = 3.6 years); the mean family income was U.S. $198.00 dollars per month, with each family member receiving 0.56 dollars per day for three daily meals. The prevalence of malnutrition was significantly higher with any of the three indices when using the NOM-SSA criteria, as compared to the WHO criteria (weight/age 91.7 vs. 30.9%; height/age 66.9 vs 17.3%; and weight/height 62.5 vs. 9.5%, respectively). CONCLUSIONS: The weight/age index and the NOM-SSA criteria overestimate the prevalence of malnutrition and are not able to tell apart children with familial small size, nor those with acute and/or chronic or past malnutrition. The WHO criteria were found to be more useful; the weight/height (recent malnutrition) and height/age (chronic malnutrition) indices should be used for international comparisons. The English version of this paper is available at: http://www.insp.mx/salud/index.html

[Interpretation of anthropometric indices in children in Arandas, Jalisco, Mexico]

OBJECTIVE: To assess the nutritional status of children attending the Instituto Alteno para el Desarrollo de Jalisco (Highlands Institute for Development of Jalisco State, Inadej) in Arandas, Jalisco and to discuss the classification criteria of infant malnutrition in Mexico. MATERIAL AND METHODS: A cross-sectional study was conducted in 775 children aged between twelve and one hundred and twenty months, who attended Inadej, including 432 children recently registered in INADEJ. Measurements included weight/age, height/age, and weight/height indices. The prevalence of malnutrition was compared using the WHO's criteria and the Mexican Official Norm Classification (NOM-SSA) criteria. The weight/age, height/age and weight/height indices were compared using the chi-squared test. RESULTS: Parents' schooling level was low (mean = 3.6 years); the mean family income was U.S. $198.00 dollars per month, with each family member receiving 0.56 dollars per day for three daily meals. The prevalence of malnutrition was significantly higher with any of the three indices when using the NOM-SSA criteria, as compared to the WHO criteria (weight/age 91.7 vs. 30.9%; height/age 66.9 vs 17.3%; and weight/height 62.5 vs. 9.5%, respectively). CONCLUSIONS: The weight/age index and the NOM-SSA criteria overestimate the prevalence of malnutrition and are not able to tell apart children with familial small size, nor those with acute and/or chronic or past malnutrition. The WHO criteria were found to be more useful; the weight/height (recent malnutrition) and height/age (chronic malnutrition) indices should be used for international comparisons. The English version of this paper is available at: http://www.insp.mx/salud/index.html

Prenatal Alcohol Exposure in Rats Diminishes Postnatal Cxcl16 Chemokine Ligand Brain Expression

Maternal ethanol consumption during pregnancy is one of the main causes of Neurodevelopmental disorders (NDD). Prenatal alcohol exposure (PAE) produces several adverse manifestations. Even low or moderate intake has been associated with long-lasting behavioral and cognitive impairment in offspring. In this study we examined the gene expression profile in the rat nucleus accumbens using microarrays, comparing animals exposed prenatally to ethanol and controls. Microarray gene expression showed an overall downward regulatory effect of PAE. Gene cluster analysis reveals that the gene groups most affected are related to transcription regulation, transcription factors and homeobox genes. We focus on the expression of the C-X-C motif chemokine ligand 16 (Cxcl16) which was differentially expressed. There is a significant reduction in the expression of this chemokine throughout the brain under PAE conditions, evidenced here by quantitative polymerase chain reaction qPCR and immunohistochemistry. Chemokines are involved in neuroprotection and implicated in alcohol-induced brain damage and neuroinflammation in the developing central nervous system (CNS), therefore, the significance of the overall decrease in Cxcl16 expression in the brain as a consequence of PAE may reflect a reduced ability in neuroprotection against subsequent conditions, such as excitotoxic damage, inflammatory processes or even hypoxic-ischemic insult